A second CD89-C57BL/6-Tg transgenic mouse model, however, was characterized by mesangial IgA deposition and hematuria controlled by a human CD11b promotor, and IgAN developed at an age of 12 weeks[21], suggesting a prominent role for CD89 in IgAN development. The gene discussed is FCAR; the disease is Hematuria.